Linked Life Data

20576011

Source:http://linkedlifedata.com/resource/pubmed/id/20576011

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2010-12-3
pubmed:databankReference
pubmed:abstractText
Rituximab may cause reactivation of hepatitis B virus (HBV) even in patients with remote HBV infection. Thus, the presence of hepatitis B core antibodies (anti-HBc) was an exclusion criterion for a randomized trial of rituximab for patients with immune thrombocytopenia. A high seroprevalence of anti-HBc observed among patients screened for the trial prompted this substudy to investigate for an association between anti-HBc seropositivity and exposure to intravenous immunoglobulin (IVIG).
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1537-2995
pubmed:author
pubmed:copyrightInfo
© 2010 American Association of Blood Banks.
pubmed:issnType
Electronic
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2577-81
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia.
pubmed:affiliation
Department of Medicine, Michael DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. arnold@mcmaster.ca
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Evaluation Studies